key: cord-0932123-93l3pfe0 authors: Garcia-Albeniz, X.; Del Amo, J.; Polo, R.; Morales Asencio, J. M.; Hernan, M. A. title: Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19 date: 2020-09-29 journal: nan DOI: 10.1101/2020.09.29.20203869 sha: bb3743918892ae737a6f55520625d3fa08baa987 doc_id: 932123 cord_uid: 93l3pfe0 Background: There is disagreement about whether hydroxychloroquine (HCQ) is effective as prophylaxis for COVID-19. We conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19. Methods and Findings: A search of PubMed, Embase, medRxiv, and clinicaltrials.gov found three completed randomized trials: one pre-exposure prophylaxis trial and two post-exposure prophylaxis trials. We obtained or calculated the risk ratio of COVID-19 diagnosis for assignment to HCQ versus no HCQ (either placebo or usual care) for each trial, and then pooled the risk ratio estimates. The risk ratio estimated for each of the individual trials were 0.74 (95% CI 0.50-1.10), 0.83 (95% CI: 0.58-1.18), and 0.69 (95% CI: 0.35-1.37). The pooled risk ratio estimate was 0.78 (95% CI: 0.61-0.99). All three trials found a similar rate of adverse effects in the HCQ and no HCQ groups. Discussion: The available evidence indicates that HCQ reduces the risk of COVID-19 by about 20%. Yet the findings from the randomized trials were widely interpreted as evidence of lack of effectiveness of HCQ, simply because they were not statistically significant when taking them individually. Completion of the ongoing prophylaxis trials is needed to generate more precise estimates of the effectiveness of HCQ to prevent COVID-19. pooled the risk ratio estimates. The risk ratio estimated for each of the individual trials were 0.74 (95% CI 0.50-1.10), 0.83 (95% CI: 0.58-1.18), and 0.69 (95% CI: 0.35-1.37). The pooled risk ratio estimate was 0.78 (95% CI: 0.61-0.99). All three trials found a similar rate of adverse effects in the HCQ and no HCQ groups. The available evidence indicates that HCQ reduces the risk of COVID-19 by about 20%. Yet the findings from the randomized trials were widely interpreted as evidence of lack of effectiveness of HCQ, simply because they were not "statistically significant" when taking them individually. Completion of the ongoing prophylaxis trials is needed to generate more precise estimates of the effectiveness of HCQ to prevent COVID-19. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.29.20203869 doi: medRxiv preprint 3 Background Hydroxychloroquine (HCQ) is not an effective treatment for established COVID-19 (1-4). However, there is disagreement about whether HCQ is effective as prophylaxis for COVID-19. We conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19 either before known exposure to an infected individual (pre-exposure prophylaxis) or after known exposure to an infected individual (postexposure prophylaxis). A search of PubMed, Embase, medRxiv, and clinicaltrials.gov found 9 ongoing randomized trials (5-13) and three that have been completed: one pre-exposure prophylaxis trial (14) and two post-exposure prophylaxis trials (15, 16) . We obtained or calculated the risk ratio of COVID-19 diagnosis for assignment to HCQ versus no HCQ (either placebo or usual care) for each of the completed trials. When the trial included both PCR-positive and PCR-negative individuals at baseline, we restricted our attention to the PCR-negative individuals. We then pooled the risk ratio estimates using both fixed effect and random effects meta-analytic approaches. The Figure shows the risk ratio estimates from each of the three trials trial and the pooled estimates. The first trial was a double-blinded, placebo-controlled trial of pre-exposure prophylaxis (available as a preprint) that included healthcare workers with ongoing exposure to patients with COVID-19. There were 58 cases (11 confirmed by PCR) among 989 (5.9%) participants assigned to HCQ (two 400 mg doses on day 1, followed by 400 mg either once or twice weekly for 12 weeks) and 39 cases (6 confirmed by PCR) among 494 (7.9%) participants is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.29.20203869 doi: medRxiv preprint assigned to placebo. The risk difference can be calculated as -2.0% (95% CI -4.8 to 0.8) and the risk ratio can be calculated as 0.74 (95% CI 0.50-1.10). The second trial was a double-blind, placebo-controlled trial of post-exposure prophylaxis (15) included asymptomatic contacts of confirmed COVID-19 cases. The risk of COVID-19 diagnosis (largely based on compatible symptoms) was 11.8% in 414 contacts assigned to HCQ (800 mg. on day 1, 600 mg. daily for four days), and 14.3% in 407 contacts assigned to placebo. The risk difference was -2.4% (95% CI: -7.0 to 2.2) and the risk ratio can be calculated as 0.83 (95% CI: 0.58-1.18). The third trial was an open-label, cluster-randomized trial of post-exposure prophylaxis (16) (available as a preprint) that included asymptomatic contacts of confirmed COVID-19 cases. The COVID-19 risk was 3.0% in 958 contacts assigned to HCQ (800 mg. on day 1, 400 mg. daily for six days), and 4.3% in 1042 contacts assigned to usual care. The risk ratio (adjusted for age, gender, region and time of exposure) was 0.69 (95% CI: 0.35-1.37); the corresponding risk difference cannot be directly calculated from the data provided. The pooled risk ratio estimated from the three trials was 0.78 (95% CI: 0.61-0.99). All three trials found a similar rate of adverse effects in the HCQ and no HCQ groups. When considered together, the available randomized trials of HCQ for the prevention of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.29.20203869 doi: medRxiv preprint 5 (none was enrolled later); in the other, participants were enrolled up to 7 days after exposure. For comparison, post-exposure prophylaxis for HIV is recommended in the first 6-72h after the exposure (17) . Pending final publication, these trials suggests a 20% reduction of COVID-19 risk attributed to HCQ, with no increased risk of serious side effects. Yet the findings from the trials were widely (and incorrectly) interpreted as evidence of lack of effectiveness of HCQ, simply because they were not "statistically significant" when taking them individually. Completion of the ongoing prophylaxis trials is needed to generate more precise estimates of the effectiveness of HCQ to prevent COVID-19. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.29.20203869 doi: medRxiv preprint Dietary reduction of serum cholesterol concentration: time to think again Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given pregnancy and/or delivery Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers Vitamin A deficiency and maternal-infant transmission of HIV in two metropolitan areas in the United States Preexposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus Ceara NDPEDDMDUFD. COVID-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare Workers Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease Prevalence of high blood cholesterol among US adults . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 29, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted September 29, 2020. . https://doi.org/10.1101/2020.09.29.20203869 doi: medRxiv preprint